Invicta Diagnostic IPO Details
| Detail | Description |
|---|---|
| IPO Date | December 1, 2025 to December 3, 2025 |
| Listing Date | [.] |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 80 to ₹ 85 per share |
| Lot Size | 1,600 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 33,08,800 shares (aggregating up to ₹ 28.12 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 92,63,173 shares |
| Share Holding Post Issue | 1,25,71,973 shares |
About Invicta Diagnostic IPO
The Invicta Diagnostic IPO opens for subscription on December 1, 2025 and closes on December 3, 2025. The book build issue of ₹28.12 crore is entirely a fresh issue of 0.33 crore shares of ₹28.12 crore. The allotment for the Invicta Diagnostic IPO is expected to be finalized on December 4, 2025. The Invicta Diagnostic IPO will list on NSE SME with a tentative listing date fixed as December 8, 2025.
The IPO price band is set at ₹80.00 to ₹85.00 per share and the lot size for an application is 1,600. The minimum amount of investment required by an individual investor (retail) is ₹2,72,000.00 (3,200 shares) (based on upper price) and the minimum lot size investment for HNI is 3 lots (4,800 shares), amounting to ₹4,08,000. Bigshare Services Pvt.Ltd. is the registrar of the issue and Socradamus Capital Pvt.Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Company Background
A Mumbai-headquartered diagnostic services company, Invicta Diagnostics operates under the brand “PC Diagnostics.” In January 2021, the company was initially incorporated as a Limited Liability Partnership. It subsequently converted to a private limited company in December 2023 before becoming a public limited company in 2024.
The founders, Dr. Ketan Jayantilal Jain and Dr. Sanket Vinod Jain are experienced radiologists who bring over 15 and 7 years, respectively, in the diagnostics sector. Invicta Diagnostics is positioned to serve the Mumbai Metropolitan Region (MMR) with an emphasis on advanced radiology and pathology diagnostics, focusing on growth and expansion through capital infusion via its IPO planned on NSE Emerge in 2025.
Operations And Product Range
Invicta Diagnostics operates a comprehensive network of diagnostic centers using a hub-and-spoke model across Mumbai and its suburbs. The company's flagship hub in Thane supports a wide range of pathology and radiology services, including 60 routine and 487 specialized pathology tests, alongside 96 basic and 130 advanced radiology tests such as CT scans, MRI and PET CT.
The spokes function primarily as sample collection points offering basic tests like sonography and X-rays, with larger hubs equipped for more advanced diagnostics. The product range of the company spans biochemistry, clinical pathology, molecular diagnostics and advanced imaging, catering to approximately 1,03,602 patients as of March 2025.
Revenue Channels
Invicta Diagnostics generates its revenue primarily through diagnostic testing services while capitalizing on increased patient footfall and expanding its portfolio of advanced diagnostic offerings. Its revenue surged by 90 percent from ₹15.83 crore in FY24 to ₹30.09 crore in FY25, with profit after tax growing from ₹3.80 crore to ₹4.92 crore. The IPO will help the company fund capital expenditure for establishing five new diagnostic centers across Maharashtra to strengthen its market presence, with the rest allocated for corporate purposes.
Management And Shareholding
The Promoters of the Company are Dr. Ketan Jayantilal Jain, Dr. Sanket Vinod Jain, Rohit Prakash Srivastava, Badal Kailash Naredi and Jayesh Prakash Jain. Recent shareholding includes notable investors such as Acharya Manish Grover, who acquired a 1.37% stake, indicating solid investor confidence ahead of the IPO.
Invicta Diagnostic IPO Objectives
The Invicta Diagnostic IPO proposes to utilize the Net Proceeds from the issue as follows: ₹21.11 crores for funding capital expenditure for the purchase of medical equipment towards the establishment of five new diagnostic centres in Maharashtra and general corporate purposes.
Conclusion
The Invicta Diagnostic IPO opens for subscription on December 1, 2025 and closes on December 3, 2025. The book build issue of ₹28.12 crore is entirely a fresh issue of 0.33 crore shares of ₹28.12 crore.
A Mumbai-headquartered diagnostic services company, Invicta Diagnostics operates under the brand “PC Diagnostics.” Invicta Diagnostics operates a comprehensive network of diagnostic centers using a hub-and-spoke model across Mumbai and its suburbs. The company's flagship hub in Thane supports a wide range of pathology and radiology services, including 60 routine and 487 specialized pathology tests, alongside 96 basic and 130 advanced radiology tests such as CT scans, MRI and PET CT.
Invicta Diagnostic IPO Financial Information
Latest Revenue
30.18
₹ Crore
Profit After Tax
4.93
₹ Crore
Net Worth
13.60
₹ Crore
Total Borrowing
3.54
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Total Borrowing | ||||
|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 21.22 | 30.18 | 4.93 | 13.60 | 3.54 | ||||
| 31 Mar 2024 | 15.89 | 15.90 | 3.81 | 8.67 | 3.81 | ||||
| Amount in ₹ Crore | |||||||||
Invicta Diagnostic Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 44.28% |
| ROCE | 42.00% |
| Debt/Equity | 0.26 |
| RoNW | 36.25% |
| PAT Margin | 16.38% |
| EBITDA Margin | 30.57% |
| Price to Book Value | 5.26 |
| Market Capitalization | ₹106.86 Cr. |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 5.32 | 3.92 |
| P/E (x) | 15.97 | 21.68 |
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Comprehensive diagnostic test portfolio across pathology and radiology
Robust recent revenue and profit growth
Experienced founders with deep domain expertise
Strategic expansion plans funded by IPO capital
Advanced diagnostic technologies and skilled personnel
Strong investor confidence and shareholding support
Download regulatory filings
Invicta Diagnostic IPO Timeline
| IPO Open Date | December 1, 2025 |
| IPO Close Date | December 3, 2025 |
| Tentative Allotment | December 4, 2025 |
| Initiation of Refunds | December 5, 2025 |
| Credit of Shares to Demat | December 5, 2025 |
| Tentative Listing Date | December 8, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Wednesday, December 3, 2025 |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 3,200 | ₹2,72,000 |
| Individual investors (Retail) (Max) | 2 | 3,200 | ₹2,72,000 |
| S-HNI (Min) | 3 | 4,800 | ₹4,08,000 |
| S-HNI (Max) | 7 | 11,200 | ₹9,52,000 |
| B-HNI (Min) | 8 | 12,800 | ₹10,88,000 |